breast cancer
Conditions
Interventions
Treatment regimen containing inizumab:No intervention measures
Sponsors
Tianjin Medical University Second Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Female patients aged = 18 years and = 70 years; 2. HER2 positive invasive breast cancer confirmed by pathological test, HER2 positive: immunohistochemical staining (IHC) showed that HER2 was 3+and/or fluorescence in situ hybridization (FISH) positive; 3. Patients who meet the indications for neoadjuvant and/or adjuvant therapy and plan to receive treatment regimen containing inizumab; 4. Cardiac ultrasound: Left ventricular ejection fraction (LVEF) = 50%; 5. Adequate organ function; 6. Volunteer to join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: Allergic constitution or known history of allergies to the ingredients of the study drug; 2. Patients with severe heart disease or discomfort who cannot receive treatment; 3. Patients with mental illness or substance abuse who cannot cooperate; 4. Pregnant or lactating female patients who are unable to take effective contraceptive measures throughout the entire trial period; 5. Any other circumstances that the researcher deems unsuitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tPCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| invasive disease-free survival,iDFS;Adverse Event, AE ;Significant Adverse Event, SAE;Severe Adverse Event, SAE; | — |
Countries
CHINA
Contacts
Public Contactyangshaoshi
Tianjin Medical University Second Hospital
Outcome results
None listed